Unicycive Therapeutics to Participate in Upcoming Investor Events in DecemberGlobeNewswireNovember 25, 2025LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December.
Event: Piper Sandler 37th Annual Healthcare ConferenceType: Fireside chatDate/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET
Event: Noble Capital Markets Virtual PresentationDate/Time: Wednesday, December 10, 2025, at 10:00 a.m. PT
A link to the live and archived Piper Sandler webcast, as well as an archived link of the Noble presentation, may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Piper Sandler conference representative.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com
Media Contact:
Layne LitsingerReal Chemistryllitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
COMTEX_470532633/2010/2025-11-25T07:05:00
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December.
Event: Piper Sandler 37th Annual Healthcare ConferenceType: Fireside chatDate/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET
Event: Noble Capital Markets Virtual PresentationDate/Time: Wednesday, December 10, 2025, at 10:00 a.m. PT
A link to the live and archived Piper Sandler webcast, as well as an archived link of the Noble presentation, may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Piper Sandler conference representative.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com
Media Contact:
Layne LitsingerReal Chemistryllitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
COMTEX_470532633/2010/2025-11-25T07:05:00
2.81% $0.18
